Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

ABSTRACT: BACKGROUND:Dasatinib is a potent BCR-ABL1 and Src family tyrosine kinase inhibitor. It is approved at a dose of 100 mg orally daily for the treatment of chronic myeloid leukemia in chronic phase (CML-CP). This dose schedule is associated with myelosuppression and pleural effusions. Anecdotal data suggest that lower doses may be as effective and less toxic. The aim of this study was to assess the efficacy and safety of a lower dose of dasatinib (50 mg daily) in patients with newly diagnosed CML-CP. METHODS:Seventy-five patients with newly diagnosed CML-CP received dasatinib 50 mg daily. The eligibility and response criteria were standards used in previous protocols. RESULTS:At a median follow-up of 9 months, 60 patients were evaluable for a response at 3 months. The rates of patients achiev

SUBMITTER: Naqvi K 

PROVIDER: S-EPMC6388399 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature